WaveMan
WaveMan · Company
MGRX · Mangoceuticals, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

MGRX Mangoceuticals (MGRX) Insider Trading, Ownership & Congress Trades

Healthcare Services · Services-misc health & allied services, nec · CIK 0001938046
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
7
13F, latest reported quarter

Mangoceuticals insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for MANGOCEUTICALS, INC. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
JOHNSTON EUGENE M
CFO
SELL
2025-12-17 SECtraded 2025-12-15
3,333
$3.9K
-81.4%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Dec 9, 2025.
  • The trade is 2.8% of the 120,000 shares held after it.
  • 1 other insider sold within 30 days.
  • 7 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CFO JOHNSTON EUGENE M sold about $3.9K of MGRX on Dec 15, 2025; 1 other insider sold within 30 days and 7 funds added in the latest 13F quarter.
JOHNSTON EUGENE M
CFO
SELL
2025-12-11 SECtraded 2025-12-09
5,000
$6.0K
-78.4%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Dec 5, 2025.
  • The trade is 4.1% of the 123,333 shares held after it.
  • 1 other insider sold within 30 days.
  • 7 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CFO JOHNSTON EUGENE M sold about $6.0K of MGRX on Dec 9, 2025; 1 other insider sold within 30 days and 7 funds added in the latest 13F quarter.
JOHNSTON EUGENE M
CFO
SELL
2025-12-09 SECtraded 2025-12-05
10,000
$11.3K
-77.8%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 7.8% of the 128,333 shares held after it.
  • 1 other insider sold within 30 days.
  • 7 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CFO JOHNSTON EUGENE M sold about $11.3K of MGRX on Dec 5, 2025; 1 other insider sold within 30 days and 7 funds added in the latest 13F quarter.
Hamilton Alex P.
Director
SELL
2025-11-26 SECtraded 2025-11-19
125,000
$152.5K
-78.0%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Jun 26, 2024.
  • The trade is 3749.3% of the 3,334 shares held after it.
  • 1 other insider sold within 30 days.
  • 7 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Hamilton Alex P. sold about $152.5K of MGRX on Nov 19, 2025, the largest insider sale at the company on our record; 1 other insider sold within 30 days and 7 funds added in the latest 13F quarter.
Hamilton Alex P.
Director
SELL
2024-06-27 SECtraded 2024-06-26
108,426
$34.7K
-94.6%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jun 25, 2024.
  • The trade is 216.9% of the 50,000 shares held after it.
  • No other insider sold within 30 days.
  • 7 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Hamilton Alex P. sold about $34.7K of MGRX on Jun 26, 2024, the largest insider sale at the company on our record; 7 funds added in the latest 13F quarter.
7 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 2 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
7 funds bought in last quarter
below 96% of Healthcare Services
Revenue
-26.0% year over year
below 91% of Healthcare Services
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
2.8% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 64% of Healthcare Services
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch MGRX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-89.5%12M
-93%-62%-31%+0%2025-102025-122026-022026-042026-062026-082026-10 2025-11-19 · Hamilton Alex P. sold $152.5K2025-12-05 · JOHNSTON EUGENE M sold $11.3K2025-12-09 · JOHNSTON EUGENE M sold $6.0K2025-12-15 · JOHNSTON EUGENE M sold $3.9K
Insider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns MGRX: institutional holders (13F)

13F holdings, latest reported quarter
CITADEL ADVISORS LLC
338,964 sh
$128.8K
XTX Topco Ltd
186,256 sh
$70.8K
GEODE CAPITAL MANAGEMENT, LLC
156,243 sh
$59.4K
Ikarian Capital, LLC
138,146 sh
$52.5K
VANGUARD CAPITAL MANAGEMENT LLC
123,041 sh
$46.8K

Congress trades in MGRX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

MGRX planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

MGRX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$46.9K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$46.8K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$6.2K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$5.4K position · as of 2026-05-31
0.0%
Fidelity Nasdaq Composite Index Fund
$195 position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 7 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
NTRACSTLPGNYHIMSWGSPRVATDOCAVAHGHADUSSERABDSX

MGRX financials

Revenue growth
-26.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$315.2K
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
-$3.9M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-95.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-86.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on capital employed
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-74.0%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$456.0K$615.9K$731.5K$8.9K
Gross profit$250.4K$380.0K$431.5K$4.8K
Operating income-$18.0M-$8.0M-$9.2M-$2.0M
Net income-$20.6M-$8.7M-$9.2M-$2.0M
EPS (diluted)-2.17-4.80-8.58-0.19
Operating cash flow-$5.9M-$4.9M-$7.0M-$1.3M
Cash$1.5M$58.7K$739.0K$682.9K
SEC XBRL, fiscal years, as known on 2026-10-28

MGRX Stock Sonar score 4/7 axes

Find similar shapesCompare

MGRX ranks highest on risk and compliance (43rd percentile) and profitability (15th), and lowest on institutional and government (4th), among Healthcare Services peers.

Profitability
15
Inputs
  • Return on equity-95.1% · 17 pct, sector of 70
  • Return on assets-86.3% · 13 pct, sector of 88
  • Return on invested capitalthe filed year and its quarters do not reconcile, so the trailing figure is withheld
  • Return on capital employedthe filed year and its quarters do not reconcile, so the trailing figure is withheld
Growth
9
Inputs
  • Revenue growth, YoY-26.0% · 9 pct, sector of 87
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
4
Inputs
  • Funds adding, latest quarter7 · 4 pct, sector of 73
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
43
Inputs
  • Short interest, % of float+2.8% · 66 pct, sector of 95
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+17.1% · 20 pct, sector of 72
3 not measured: Financial health, Insider conviction, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies